https://www.mynewsdesk.com/se/astrazeneca/documents Mynewsdesk nyhetsfeed direkt från källan https://www.mynewsdesk.com/se/astrazeneca/documents https://www.mynewsdesk.com/assets/graphics/logos/logo-small-3b24ab90.png 128 23 sv 15 Thu, 27 Apr 2023 08:01:42 +0200 https://www.mynewsdesk.com/se/astrazeneca/documents/eng-az-results-q1-2023-dot-pdf-431283?utm_source=rss&utm_medium=rss&utm_campaign=Subscription&utm_content=document https://www.mynewsdesk.com/se/astrazeneca/documents/eng-az-results-q1-2023-dot-pdf-431283?utm_source=rss&utm_medium=rss&utm_campaign=Subscription&utm_content=document AstraZeneca AB Thu, 27 Apr 2023 08:01:42 +0200 https://www.mynewsdesk.com/se/astrazeneca/documents/svensk-sammanfattning-az-results-q1-2023-dot-pdf-431282?utm_source=rss&utm_medium=rss&utm_campaign=Subscription&utm_content=document https://www.mynewsdesk.com/se/astrazeneca/documents/svensk-sammanfattning-az-results-q1-2023-dot-pdf-431282?utm_source=rss&utm_medium=rss&utm_campaign=Subscription&utm_content=document AstraZeneca AB Thu, 09 Feb 2023 08:03:36 +0100 https://www.mynewsdesk.com/se/astrazeneca/documents/sve-az-2022-fy-dot-pdf-429012?utm_source=rss&utm_medium=rss&utm_campaign=Subscription&utm_content=document https://www.mynewsdesk.com/se/astrazeneca/documents/sve-az-2022-fy-dot-pdf-429012?utm_source=rss&utm_medium=rss&utm_campaign=Subscription&utm_content=document AstraZeneca AB Thu, 09 Feb 2023 08:03:36 +0100 https://www.mynewsdesk.com/se/astrazeneca/documents/eng-az-2022-fy-dot-pdf-429011?utm_source=rss&utm_medium=rss&utm_campaign=Subscription&utm_content=document https://www.mynewsdesk.com/se/astrazeneca/documents/eng-az-2022-fy-dot-pdf-429011?utm_source=rss&utm_medium=rss&utm_campaign=Subscription&utm_content=document AstraZeneca AB Thu, 10 Nov 2022 08:01:00 +0100 https://www.mynewsdesk.com/se/astrazeneca/documents/sve-q3-2022-final-dot-pdf-427322?utm_source=rss&utm_medium=rss&utm_campaign=Subscription&utm_content=document https://www.mynewsdesk.com/se/astrazeneca/documents/sve-q3-2022-final-dot-pdf-427322?utm_source=rss&utm_medium=rss&utm_campaign=Subscription&utm_content=document AstraZeneca AB Thu, 10 Nov 2022 08:01:00 +0100 https://www.mynewsdesk.com/se/astrazeneca/documents/eng-q3-2022-final-dot-pdf-427321?utm_source=rss&utm_medium=rss&utm_campaign=Subscription&utm_content=document https://www.mynewsdesk.com/se/astrazeneca/documents/eng-q3-2022-final-dot-pdf-427321?utm_source=rss&utm_medium=rss&utm_campaign=Subscription&utm_content=document AstraZeneca AB Fri, 29 Jul 2022 08:02:37 +0200 https://www.mynewsdesk.com/se/astrazeneca/documents/sve-az-h1-2022-final-dot-pdf-424427?utm_source=rss&utm_medium=rss&utm_campaign=Subscription&utm_content=document https://www.mynewsdesk.com/se/astrazeneca/documents/sve-az-h1-2022-final-dot-pdf-424427?utm_source=rss&utm_medium=rss&utm_campaign=Subscription&utm_content=document AstraZeneca AB Fri, 29 Jul 2022 08:02:37 +0200 https://www.mynewsdesk.com/se/astrazeneca/documents/final-azn-2022-h1-announcement-dot-pdf-424426?utm_source=rss&utm_medium=rss&utm_campaign=Subscription&utm_content=document https://www.mynewsdesk.com/se/astrazeneca/documents/final-azn-2022-h1-announcement-dot-pdf-424426?utm_source=rss&utm_medium=rss&utm_campaign=Subscription&utm_content=document AstraZeneca AB Mon, 16 May 2022 13:34:02 +0200 Äggstockscancer infografik: Reparationer av DNA-skador (Webb) https://www.mynewsdesk.com/se/astrazeneca/documents/aeggstockscancer-infografik-reparationer-av-dna-skador-webb-422774?utm_source=rss&utm_medium=rss&utm_campaign=Subscription&utm_content=document https://www.mynewsdesk.com/se/astrazeneca/documents/aeggstockscancer-infografik-reparationer-av-dna-skador-webb-422774?utm_source=rss&utm_medium=rss&utm_campaign=Subscription&utm_content=document AstraZeneca AB Mon, 16 May 2022 13:32:51 +0200 Äggstockscancer infografik: Reparationer av DNA-skador (Print) https://www.mynewsdesk.com/se/astrazeneca/documents/aeggstockscancer-infografik-reparationer-av-dna-skador-print-422773?utm_source=rss&utm_medium=rss&utm_campaign=Subscription&utm_content=document https://www.mynewsdesk.com/se/astrazeneca/documents/aeggstockscancer-infografik-reparationer-av-dna-skador-print-422773?utm_source=rss&utm_medium=rss&utm_campaign=Subscription&utm_content=document AstraZeneca AB Mon, 16 May 2022 13:31:16 +0200 Äggstockscancer infografik https://www.mynewsdesk.com/se/astrazeneca/documents/aeggstockscancer-infografik-422771?utm_source=rss&utm_medium=rss&utm_campaign=Subscription&utm_content=document https://www.mynewsdesk.com/se/astrazeneca/documents/aeggstockscancer-infografik-422771?utm_source=rss&utm_medium=rss&utm_campaign=Subscription&utm_content=document AstraZeneca AB Fri, 29 Apr 2022 08:02:25 +0200 https://www.mynewsdesk.com/se/astrazeneca/documents/az-q1-2022-english-dot-pdf-422009?utm_source=rss&utm_medium=rss&utm_campaign=Subscription&utm_content=document https://www.mynewsdesk.com/se/astrazeneca/documents/az-q1-2022-english-dot-pdf-422009?utm_source=rss&utm_medium=rss&utm_campaign=Subscription&utm_content=document AstraZeneca AB Fri, 29 Apr 2022 08:02:25 +0200 https://www.mynewsdesk.com/se/astrazeneca/documents/az-q1-2022-svenska-dot-pdf-422008?utm_source=rss&utm_medium=rss&utm_campaign=Subscription&utm_content=document https://www.mynewsdesk.com/se/astrazeneca/documents/az-q1-2022-svenska-dot-pdf-422008?utm_source=rss&utm_medium=rss&utm_campaign=Subscription&utm_content=document AstraZeneca AB Thu, 10 Feb 2022 08:02:52 +0100 Total Revenue increased by 41% and Core EPS by 32% in a year of exceptional pipeline and commercial delivery, coupled with accelerated strategic transformation through the acquisition of Alexion. https://www.mynewsdesk.com/se/astrazeneca/documents/full-year-and-q4-2021-results-419354?utm_source=rss&utm_medium=rss&utm_campaign=Subscription&utm_content=document https://www.mynewsdesk.com/se/astrazeneca/documents/full-year-and-q4-2021-results-419354?utm_source=rss&utm_medium=rss&utm_campaign=Subscription&utm_content=document AstraZeneca AB Thu, 10 Feb 2022 08:02:39 +0100 Totala intäkter ökade med 41% och vinst per aktie för kärnverksamheten ökade med 32% under ett år med en exceptionell leverans både av forskningsportföljen och kommersiellt, i kombination med en accelererad strategisk omvandling i och med förvärvet av Alexion. https://www.mynewsdesk.com/se/astrazeneca/documents/resultatrapport-foer-helaaret-och-fjaerde-kvartalet-2021-419353?utm_source=rss&utm_medium=rss&utm_campaign=Subscription&utm_content=document https://www.mynewsdesk.com/se/astrazeneca/documents/resultatrapport-foer-helaaret-och-fjaerde-kvartalet-2021-419353?utm_source=rss&utm_medium=rss&utm_campaign=Subscription&utm_content=document AstraZeneca AB Fri, 12 Nov 2021 08:02:57 +0100 https://www.mynewsdesk.com/se/astrazeneca/documents/final-se-rslt-20211112-dot-pdf-417024?utm_source=rss&utm_medium=rss&utm_campaign=Subscription&utm_content=document https://www.mynewsdesk.com/se/astrazeneca/documents/final-se-rslt-20211112-dot-pdf-417024?utm_source=rss&utm_medium=rss&utm_campaign=Subscription&utm_content=document AstraZeneca AB Fri, 12 Nov 2021 08:02:57 +0100 https://www.mynewsdesk.com/se/astrazeneca/documents/final-20211112-rslt-dot-pdf-417023?utm_source=rss&utm_medium=rss&utm_campaign=Subscription&utm_content=document https://www.mynewsdesk.com/se/astrazeneca/documents/final-20211112-rslt-dot-pdf-417023?utm_source=rss&utm_medium=rss&utm_campaign=Subscription&utm_content=document AstraZeneca AB Fri, 17 Sep 2021 13:42:20 +0200 https://www.mynewsdesk.com/se/astrazeneca/documents/her2-positiv-broestcancer-dot-pdf-413909?utm_source=rss&utm_medium=rss&utm_campaign=Subscription&utm_content=document https://www.mynewsdesk.com/se/astrazeneca/documents/her2-positiv-broestcancer-dot-pdf-413909?utm_source=rss&utm_medium=rss&utm_campaign=Subscription&utm_content=document AstraZeneca AB Fri, 17 Sep 2021 13:41:48 +0200 https://www.mynewsdesk.com/se/astrazeneca/documents/allmaent-om-broestcancer-dot-pdf-413908?utm_source=rss&utm_medium=rss&utm_campaign=Subscription&utm_content=document https://www.mynewsdesk.com/se/astrazeneca/documents/allmaent-om-broestcancer-dot-pdf-413908?utm_source=rss&utm_medium=rss&utm_campaign=Subscription&utm_content=document AstraZeneca AB Thu, 29 Jul 2021 08:04:17 +0200 https://www.mynewsdesk.com/se/astrazeneca/documents/azn-h1-2021-results-dot-pdf-412469?utm_source=rss&utm_medium=rss&utm_campaign=Subscription&utm_content=document https://www.mynewsdesk.com/se/astrazeneca/documents/azn-h1-2021-results-dot-pdf-412469?utm_source=rss&utm_medium=rss&utm_campaign=Subscription&utm_content=document AstraZeneca AB